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Background: Breast cancer remains a major health problem in the world. Triple-negative breast cancer
(TNBC) is an aggressive subtype with very poor prognosis. Up to now, the mechanism behind TNBC’s
activity is still unclear and no candidate drug target has been identified. Thus, it is of critical importance
to elucidate the pathways in TNBC and identify the relevant biomarkers. Recent studies showed that
ganglioside D3 synthase (GD3s) played a very important role in development of cancers. However, the
physiological functions and associated pathways of GD3s in TNBC are still unclear.
Methods: In silico analysis of the expression of GD3s in TNBC was conducted using The Cancer Genome
Atlas (TCGA) and Oncomine databases. The proliferation of breast cancer cells was measured by MTT
assay, colony formation by the soft agar method, and migration and invasion using Boyden chamber inserts.
The methylation level of the gene encoding GD3s, ST8SIA1, in specimens was assessed by qMS-PCR and
in silico using the UCSC gene browser. Protein expression was examined via immunohistochemistry (IHC),
qRT-PCR and Western immunoblotting.
Results: In silico analysis showed a higher GD3s expression in ER− than ER+ breast cancers and GD3s was
also highly expressed in TNBC compared to other types of breast cancers. The elevated GD3s expression
in TNBC cells and tissues was associated with hypomethylation of the ST8SIA1 gene. Overexpression of
GD3s in human breast cancer cells increased their proliferation, migration, invasion and colony formation
ability. GD3s expression in breast cancers was closely associated with relapse-free survival (RFS) and overall
survival (OS).
Conclusions: In summary, these results suggest that GD3s may be a potential biomarker and drug target
in treatment of TNBC.
Keywords: Ganglioside D3 synthase (GD3s); triple-negative breast cancer (TNBC); biomarker; methylation;
prognosis
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Introduction

Methods

Breast cancer has become the second most common cause
of mortality and morbidity in women all over the world (1).
Breast cancers have many subtypes, but there are three
main ones: ER+, HER2+ and triple-negative breast cancer
(TNBC) (2). TNBC is a very aggressive cell type with a
poor prognosis. Understanding the molecular mechanism
of TNBC malignancy should allow researchers to identify
new effective drug targets.
Gangliosides are very important in the development (3),
differentiation (4,5) and proliferation (6) of cells. Ganglioside
D3 (GD3) and ganglioside D2 (GD2) are strongly
expressed in neuroectoderm-derived cancers and thought
to be important in the malignant transformation of tumor
cells (7). The expression profiles of gangliosides in the
development and transformation of many cancers have been
determined (8,9). GD3 is highly expressed in malignant
melanomas (10,11) where it can be used as a biomarker
of human melanoma (12) since it is only expressed at low
levels in normal melanocytes (13). GD2 is overexpressed in
melanomas and small cell lung cancers where it increases
the growth and invasiveness of cells (14). GD2 was used as
a biomarker of breast stem cells (15) and mesenchymal stem
cells (16).
GD3 synthase (GD3s) is one of six members of the
ST8Sia subfamily of sialyltransferases (ST8Sia I-VI), also
known as ST8SIA1. GD2 and GD3 are highly expressed
in many malignant cancers (17-19) and GD3s is the
only enzyme that is responsible for biosynthesis of GD2
and GD3 (20). GD3s plays a very important role in the
development of cancers (21,22), but the signaling pathways
involved in GD3s activity in breast cancers like TNBC have
not been fully delineated.
In this study, we explored the expression of GD3s in
cells and tissues of different types of breast cancer and
found higher GD3s levels in ER− breast cancers than in ER+
breast cancers and a negative correlation with the signature
of luminal breast cancer. GD3s overexpression in TNBCs
was associated with hypomethylation of the synthase gene,
ST8SIA1, and resulted in increased proliferation, invasion,
migration and colony formation of cell. Inhibition of GD3s
reduced proliferation, invasion, migration and colony
formation of cell. Clinically, a lower GD3s expression was
clearly associated with relapse-free survival (RFS) and
increased overall survival (OS) of breast cancer patients.

Cell culture
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The human breast cancer cell lines, MCF-7, MDAMB-468 and T47D, were purchased from the American
Type Culture Collection. MCF-7 cells were cultured in
DMEM, while MDA-MB-468 and T47D were cultured in
RPMI 1640. Both mediums were supplemented with 10%
fetal calf serum, 100 units/mL penicillin, and 100 µg/mL
streptomycin at 37 ℃ in a humidified incubator containing
5% CO2.
Tumor specimens
The Institutional Review Board at the John Wayne Cancer
Institute/Saint John Health Center Providence Health
System, Santa Monica, CA, approved the use of human
tissues (MORD-RTPCR-0995). Immunohistochemistry
(IHC) was carried out on sections from paraffin-embedded
archival tissue (PEAT) specimens of breast cancers, which
had been diagnosed at the Saint John Health Center
Providence Health System, Santa Monica, CA.
Stable transfection
MCF-7 cells were seeded in 60 mm dishes at 70–80%
confluence for 24 h before transfection. MCF-7 cells,
which do not express GD3s, were transfected with a
GD3s expression plasmid using the transfection reagent,
Lipofectamine™ 3000, (Invitrogen, Grand Island, NY,
USA) for 24 h. The cells were then grown in the presence of
800 µg/mL G418 (Invitrogen, Grand Island, NY, USA) for
three weeks. MCF-7 cells with high GD3s expression were
referred to as MCF-7-GD3s. MDA-MB-468 cells, which
have a normally high GD3s expression level, were plated
in 60 mm dishes at 70–80% confluence for 24 h before
transfection with GD3s shRNA (Sigma-Aldrich, St. Louis,
MO, USA). Stably transfected MDA-MB-468-shRNA cells
were selected by incubation with 5 μg/mL puromycin. For
controls, MCF-7 cells were transfected with empty vector
(MCF-7-cntl) and MDA-MB-468 cells were transfected
with a control shRNA (MDA-MB-468cntl).
GD3s expression was verified by Western blotting
with anti-GD3s antibody (Abcam, Cat. No. ab214936,
Cambridge, UK), anti-myc antibody (EMD Millipore,
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Table 1 Primers for qRT-PCR
Primer

Forward

Reverse

GD3s

ACGGCGTGGAGGAGGAAC

CAAAGGAGGGAGATTGCATCG

qRT-PCR, quantitative reverse transcriptase-PCR.

Cat. No. 06-340, San Diego, CA) and anti-FLAG antibody
(Origene, Cat. No. TA50011-100, Rockville, MD, USA).
Cell growth and colony formation in soft agar
Cell proliferation was assessed by MTT [3-(4,5-dimethylthiazol-2yl)-2,5diphenyltetrazolium] assay (Sigma-Aldrich, St. Louis,
MO, USA). The colony formation assay in soft agar was
carried out in six-well culture plates. After 2–3 weeks, the
colony were stained with 5 mg/mL MTT and the number
was counted. Each experiment was done in triplicate.
Cell migration and invasion assay
About 1×10 4 cells were seeded on top of the Boyden
chamber inserts (BD Biosciences, San Jose, CA, USA) and
10% fetal calf serum was used as the chemoattractant. To
reduce the effect of cell proliferation, mitomycin C was
added to the cells to a final concentration of 2 μg/mL.
Cells that had migrated through the membrane onto the
lower surface of the inserts were stained with 1% crystal
violet and counted in four randomly selected fields using a
microscope. For invasion assays, inserts were coated with
a thin layer of Matrigel basement membrane matrix. The
subsequent steps in the invasion assay were the same as
those of the migration assay.

Genomics (http://www.cbioportal.org/) provides many
different cancer data sets, such as sequencing data,
microarray data, RNA-Seq data, etc. The cBioPortal can
also be used to assess the effects of co-expression of genes.
There is a data set of 1,881 breast tumor samples and a
51-sample breast cancer cell line set available in GOBO
(http://co.bmc.lu.se/gobo). Many different analyses can
be performed using these data sets, which were all from
Affymetrix U133A microarrays. The mRNA expression of
specific genes in cancers can be easily checked in GOBO.
The association between gene expression and patient
outcomes can also be determined by using the GOBO
dataset. The website (https://genome-cancer.ucsc.edu/proj/
site/hgHeatmap/) was used to assess the methylation of
genes in different cancers from TCGA data.
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA (1 μg) was extracted from breast cancer cell
lines and used for cDNA synthesis according to the
manufacturer’s instructions. (Qiagen, Hilden, Germany).
The cDNA was added to PCR mixture that contained
1X SYBR Green PCR master mix (Quanta Biosciences,
Gaithersburg, MD) and 300 nmol/L gene-specific GD3s
primers (AuGCT). The assays were carried out three times
on a CFX thermocycler (Bio-Rad, Hercules, CA). The
primers are given in Table 1.

In silico analysis
The Oncomine database (www.oncomine.org) is very useful
for investigating genes that are expressed in multiple cancer
datasets to validate the relationship between transcription
and disease. More advanced analyses were used to
check gene expression in a small fraction of samples of a
cancer type using different filters. The expression of GD3s
mRNA was checked in the subtypes of breast cancers.
The Cancer Genome Atlas (TCGA) was initiated by the
National Cancer Institute (NCI) and the National Human
Genome Research Institute (NHGRI) and can be utilized to
study the molecular basis of cancer through the application
of genome analysis technologies. The cBioPortal for Cancer
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Quantitative real-time methylation-specific PCR
(qMS-PCR)
Genomic DNA was extracted from MCF-7 and T47D
breast cancer cells (1×106) using a QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. The bisulfite DNA modification was performed
according to the manufacturer’s instructions and the
methylation level of the ST8SIA1 gene was determined
by qMS-PCR using two primer sets, one designed for
methylated (M) DNA and the other for unmethylated
(U) DNA. The primers for the methylation-specific PCR
and unmethylated-specific PCR of the ST8SIA1 gene
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Table 2 Primers for methylation assays
Primer

Forward

Reverse

M

GGTTTAGGAAGGAATAAATTTTCGT

CCAAACTATCACCCTACTACCGT

U

GGTTTAGGAAGGAATAAATTTTTGT

CCAAACTATCACCCTACTACCATC

M, methylated; U, unmethylated.

(Table 2) were designed using Urogene’s MethPrimer
software: (http://www.urogene.org/cgi-bin/methprimer/
methprimer.cgi).
IHC
IHC was carried out on five-micron sections from PEAT
specimens. Expression of GD3s protein was measured using
polyclonal anti-GD3s rabbit antibody (No. HPA026775,
Sigma-Aldrich, St. Louis, MO, USA) at a dilution of
1:200. Slides were deparaffinized, then rehydrated and
washed in 1X PBS. Antigen retrieval was done with citrate
buffer (Sigma-Aldrich) at 100 ℃ for 10 min. After antigen
retrieval, slides were incubated in 3% H2O2 (Sigma-Aldrich)
to block endogenous peroxidase at room temperature.
The GD3s antibody was added to the slides, which were
incubated overnight at 4 ℃, followed by 1 h incubation
with biotinylated second Ab. Staining was done with
diaminobenzidine (Vectastain, Burlingame, CA, USA) and
cells were counterstained with hematoxylin (Sigma-Aldrich).
The negative controls were treated with rabbit serum alone
(Santa Cruz Biotechnology, Dallas, TX, USA). A Nikon
Eclipse Ti microscope was used to take photograph of
stained sections and staining density was analyzed by Image
J software (http://rsbweb.nih.gov/ij/).
Western immunoblotting
Western immunoblotting analysis was done as previously
described (23). Cells were lysed in RIPA buffer on ice with
protease inhibitors (Applygen Technologies Inc., Beijing,
China) and total protein was extracted. Protein lysates
were separated on 12% polyacrylamide gels with SDSTris-glycine running buffer, transferred to polyvinylidene
difluoride (PVDF) membranes, and blocked with 5% milk
in TBST. The PVDF membranes were then incubated
overnight with primary antibodies for GD3s (Abcam, No.
ab37806, Cambridge, UK) and GAPDH (No. 10494-1-AP,
Proteintech, Wuhan, China). After washing with TBST,
the blots were incubated with HRP-conjugated secondary
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antibodies (No. 7074, anti-rabbit IgG; No. 7076, antimouse IgG, Cell Signaling Technology, Danvers, USA).
Signal detection was performed using the Pierce™ ECL
Western blotting substrate (Thermo Fisher Scientific,
Waltham, MA, USA) and Bio-Rad Imaging System
(Hercules, USA).
Statistical analysis
The results are given as mean ± SD. Statistical significance
between different group was assessed by Student’s t-test. A
P<0.05 was considered to be statistically significant.
Results
GD3s was inversely associated with signature biomarkers
of luminal breast cancers: ESR1, FOXA1, GATA3, XBP1
and MYB
To explore the association between GD3s and the
biomarkers of luminal breast cancers, we downloaded and
analyzed the co-expression data for GD3s from TCGA
(http://www.cbioportal.org/public-portal/cross_cancer.do).
The results showed that GD3s mRNA expression was
inversely correlated with expression of the luminal breast
cancer markers, ESR1, GATA3, FOXA1, MYB and XBP1
mRNA (Figure 1A,B,C,D,E). The expression of GD3s
mRNA was positively associated with FOXC1, which is a
biomarker of TNBC (24) (Figure 1F). Overall, these results
suggest that GD3s may be a potential biomarker of luminal
breast cancer and TNBC.
Expression of GD3s in ER- breast cancers was higher than
in ER+ breast cancers
To test the association between GD3s and ER in breast
cancers, we did an in silico assay to compare the expression
of GD3s in breast cancer patients with ER+ or ER- cell types
using the Oncomine database. There was much higher
GD3s expression in breast cancer patients that were ERcompared to those who were ER+ (Figure 2).
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Figure 1 GD3s is inversely correlated with signatures of luminal breast cancers, ESR1, FOXA1, GATA3, XBP1 and MYB. GD3s is inversely
correlated with (A) ESR1, (B) FOXA1, (C) GATA3, (D) XBP1, and (E) MYB. GD3s is positively correlated with (F) FOXC1, which is a
biomarker of BLBC.

GD3s was highly expressed in TNBCs
We compared GD3s expression in TNBCs with that in
other types of breast cancers using data from Oncomine and
TCGA. Expression of GD3s was much higher in TNBCs
than other types of breast cancer (Figure 3A,B,C,D,E).
To determine the levels of GD3s mRNA and protein
expression in breast cancer cell lines, qRT-PCR and
Western blotting were carried out. The expression of GD3s
mRNA and protein in TNBC cells was significantly higher
than that in other breast cancer cell lines (Figure 3F,G).
GD3s promoted proliferation, invasion, migration and
colony formation of breast cancer cells
To investigate the functional roles of GD3s in breast cancer,
MCF-7 cells which normally have low GD3s expression
were transfected with a GD3s expression plasmid. The
MDA-MB-468 cell line, which normally has high GD3s
expression, was transfected with GD3s shRNA that blocks
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transcription of the GD3s gene. Controls (cntl) were empty
vector for MCF-7 and control shRNA for the MDA cell
line. MCF-7-cntl, MCF-7-GD3s, MDA-MB-468-cntl, and
MDA-MB-468-shRNA were tested for cell proliferation,
migration, invasion and colony formation. Overexpression
of GD3s promoted proliferation, invasion, migration and
colony formation, whereas knockdown of GD3s inhibited
these functions (Figure 4).
GD3s expression was associated with methylation of the
ST8SIA1 gene
To determine if GD3s expression was associated with
methylation of the ST8SIA1 gene, in silico analysis using the
UCSC gene browser (http://genome.ucsc.edu) was carried
out. Results showed that there was a 102 bp CpG island in
the promoter region of the ST8SIA1 gene (Figure 5A and
Figure S1). Data from TCGA demonstrated that expression
of GD3s was inversely correlated with methylation of
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Figure 2 GD3s expression is significantly higher in ER+ breast cancer than ER−. (A,B,C,D,E) GD3s expression is higher in ER+ breast
cancer than ER−. Data and statistics were obtained from www.oncomine.org (TCGA 2011; Richardson et al., 2006; Curtis et al., 2012; Gluck
et al., 2011; Zhao et al., 2004).

the ST8SIA1 gene (Figure 5B) and that survival rate of
patients with breast cancers was significantly associated with
methylation of ST8SIA1 gene (Figure 5C). Results from a
methylation array of TCGA data (https://genome-cancer.
ucsc.edu/proj/site/hgHeatmap/) showed that there was
significantly less methylation of ST8SIA1 gene in TCGA
breast cancer tissues (Figure 5D). To further explore the
association between GD3s expression and methylation of
ST8SIA1 gene in breast cancer cells, MS-PCR was used to
assess the methylation level in the ST8SIA1 gene promoter
in eight breast cancer cell lines: MCF7, MDA-MB-468,
T47D, ZR751, MDA-MB-231, BT549, MDA-MB-436,
and HCC1143, plus a non-tumor cell line MCF-10A. The
methylation levels of the ST8SIA1 gene promoter in the
breast cancer cell lines were significantly lower (P<0.05)
than in MCF-10A cells (Figure 5E). To further explore if
ST8SIA1 gene expression was regulated by methylation,
we treated MCF-7 cells and T47D cells, which had low
GD3s expression, with the methyl transferase inhibitor,
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5-azacytidine, or with vehicle control (DMSO). GD3s
expression in MCF-7 cells and T47D cells incubated
with 5-azacytidine was increased compared to controls
(Figure 5F). In sum, our results demonstrated that
GD3s expression in breast cancer cells was regulated by
methylation of ST8SIA1.
GD3s was overexpressed in TNBC tissues and associated
with reduced OS and RFS
IHC was performed to determine if TNBCs had greater
GD3s protein levels than estrogen- or progesteronereceptor-positive luminal breast cancers. Results showed
that staining density of GD3s was significantly higher in
TNBCs compared to luminal breast cancers (Figure 6A,B).
To ascertain whether expression of GD3s affected the
survival of patients with breast cancer, Kaplan Meier
analyses were carried out. It was shown that patients with
high GD3s had lower survival rates, while patients with low
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Figure 3 GD3s is highly expressed in TNBCs. (A,B,C,D,E) GD3s expression is higher in TNBC than other types of breast cancers.
Data and statistics were obtained from www.oncomine.org (TCGA 2011; Richardson et al., 2006; Curtis et al., 2012; Zhao et al.,
2004; Turashvili et al., 2007); (F) GD3s mRNA expression is higher in TNBC cell lines (MDA-MB-231, MDA-MB-435 and HCC1143)
than other types of breast cancer cell lines (MCF-7, T47D, BT47D and ZR75-1); (G) GD3s protein expression is higher in TNBC cell lines
(MDA-MB-231, MDA-MB-435 and HCC1143) than other types of breast cancer cell lines (MCF-7, T47D, BT47D and ZR75-1).

GD3s had higher survival rates (Figure 6C). Results from

Discussion

an in silico assay confirmed the survival data (Figure 6D)

Breast cancers are commonly classified into three subtypes,
ER + , HER2 + and TNBC (2). TNBC has the worst
prognosis. Up to now, there has been no drug specifically

and showed that low GD3s expression was significantly
associated with RFS of breast cancer patients (Figure S2).
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Figure 4 GD3s promotes proliferation, migration, invasion and colony formation of breast cancer cells. (A) Overexpression of GD3s promotes
proliferation of MCF-7 cells while knockdown of GD3s inhibits proliferation of MDA-MB-468; (B) overexpression of GD3s increases migration
of MCF-7 cells while knockdown of GD3s reduces migration of MDA-MB-468; (C) overexpression of GD3s increases invasion of MCF-7 cells
while knockdown of GD3s reduces invasion of MDA-MB-468 (stained with 1% crystal violet); (D) overexpression of GD3s promotes colony
formation of MCF-7 cells while knockdown of GD3s inhibited colony formation of MDA-MB-468, stained with 5 mg/mL MTT.

targeting TNBC and the molecular mechanisms controlling
TNBC’s malignancy were unclear. Here, we reported
that the ganglioside synthase, GD3s, was associated
with luminal breast cancer and highly expressed in ER −
tumors and TNBC. Expression of GD3s was regulated by
methylation of the synthase gene, ST8SIA1 and promoted
the proliferation, migration invasion and colony formation
of cancer cells. In terms of survival, higher expression levels
of GD3s were significantly associated with lower RFS and
lower OS of breast cancer patients.
GD2 and GD3 are highly expressed in a variety of

© Annals of Translational Medicine. All rights reserved.

malignant tumors (25). GD3s is the sole enzyme responsible
for biosynthesis of GD3 and GD2 (20). Recent studies
showed that GD3s was highly expressed in many cancers
and was very important in the development of cancers
(25,26). In this study, data from TCGA showed that GD3s
was negatively correlated with the signatures of luminal
breast cancers: ESR1, FOXA1, GATA3, XBP1 and MYB.
We also found that GD3s expression was much higher in
ER- breast cancers than in ER+ and in TNBCs compared to
luminal breast cancers. Results from IHC showed that there
was much higher expression of GD3s protein in patients

Ann Transl Med 2019;7(23):723 | http://dx.doi.org/10.21037/atm.2019.12.23

Annals of Translational Medicine, Vol 7, No 23 December 2019

B

C
12
10

DNA methylationMethylation 450k

1.0

Pearson: −0.555
Spearman: −0.588

Survival percentage

GD3s mRNA expression

A

Page 9 of 12

8
6
4
2
0 8
−0.2 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

0.75
0.5
P=0.04007
<0.3488 (n=440)
≥0.3488 (n=443)

0.25
0

1 2 3 4 5 6 7 8
Days (103)

GD3s methylation

E
12
10
8

DMSO
5'-AZA

6
4

HCC1143

BT549

MDA-MB-436

MDA-MB-231

T47D

GAPDH

ZR751

GD3s

0

MCF-7

2
MDA-MB-468

GD3s

F

MCF-10A

Relative methylation level

TCGA breast invasive carcinoma (BRCA) DNA
methylation (Human methylation 450) N=872

Methylation level

D

MCF-7

T47D

+
−

+
−

+
+

+
+

Figure 5 GD3s expression is associated with methylation of the ST8SIA1 gene. (A) A 102 bp CpG island is present in the promoter region
of the ST8SIA1 gene; (B) expression of GD3s is negatively correlated with methylation of ST8SIA1; (C) survival rate of patients with breast
cancers is significantly associated with methylation of ST8SIA1; (D) methylation of ST8SIA1 is significantly lower in TCGA breast cancer
tissues; (E) methylation levels of ST8SIA1 gene promoter in eight breast cancer cell lines are significantly lower (P<0.05) than in non-tumor
MCF-10A cells; (F) GD3s expression in MCF-7 cells and T47D cells treated with 5-azacytidine are increased compared to controls.

with TNBC than other types of breast cancer. All these
results suggested that GD3s was not only associated with
ER- breast cancers but also with TNBC.
It was reported that cell migration and colony formation
in MDA-MB-468 and MDA-MB-231 cell lines was
reduced if expression of GD3s was knocked down by GD3s
shRNA (27). Our results showed that GD3s over-expression
in MCF-7 cells increased proliferation, migration, invasion
and colony formation while knockdown of GD3s inhibited
proliferation, invasion, migration and colony formation
of cells in MDA-MB-468. Our results confirmed previous
evidence in part and further suggested that GD3s played
an important functional role in the development of breast
cancer. Targeting GD3s inhibited proliferation and
mobility, suggesting that GD3s may be a feasible drug
target for breast cancer therapy, especially for TNBC.
Epigenetic regulation is an important mechanism for
controlling gene expression and plays key roles in many
processes of life, such as development (28,29), as well as in

© Annals of Translational Medicine. All rights reserved.

diseases like cancer (30,31). We identified a 102 bp CpG
island in the promoter region of the ST8SIA1 gene, and
showed that GD3s expression was inversely associated
with methylation of the ST8SIA1 synthase gene. Further
experiments proved that GD3s expression was increased by
demethylation of ST8SIA1. Overexpression of GD3s caused
by hypomethylation of ST8SIA1 promoted the development
of breast cancer and lowered patients’ survival rates. Taken
together, these results showed that GD3s expression was
regulated by ST8SIA1 gene methylation and that higher
GD3s activity was associated with development of breast
cancers.
TNBC patients have a poor prognosis and lower OS
compared to patients with luminal breast cancer. This may
be a result of GD3s over-expression that increases cell
proliferation, migration, invasion and colony formation
of tumor cells. Higher GD3s expression was first noted
in patients with lower rates of OS, relapse-free survival,
and distant metastasis-free survival of all breast cancers at
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Figure 6 Expression of GD3s protein is much higher in TNBC than luminal breast cancer. (A) Representative pictures of luminal (left) and triple
negative breast cancer (right). Staining was done with diaminobenzidine and cells were counterstained with hematoxylin; (B) expression of GD3s is
significantly higher in TNBC compared to luminal breast cancer; (C) expression of GD3s is significantly associated with overall survival (OS) in all
patients with breast cancer; (D) expression of GD3s is significantly associated with OS in all patients with breast cancer in TCGA data.

grade 3 (Figures S3-S5). GD3s may be used as a biomarker
for staging breast cancers and as a potential drug target in
the future.
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Figure S1 ST8SIA1 gene 1,000 bp promoter.
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Figure S2 Expression of GD3s is significantly associated with relapse-free survival in patients with breast cancer.
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Figure S3 Expression of GD3s is significantly associated with overall survival in patients with grade 3 breast cancer.
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Figure S4 Expression of GD3s is significantly associated with relapse-free survival in patients with grade 3 breast cancer.
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Figure S5 Expression of GD3s is significantly associated with distant metastasis-free survival in patients with grade 3 breast cancer.

